One to measure cobalamin levels and the other for Anti-Intrinsic factor antibody (Anti-IFAB) to confirm the presence of pernicious anaemia
Although their direct therapeutic application is limited by poor membrane permeability, rapid dephosphorylation, and unfavorable pharmacokinetic properties, phosphopeptides are privileged molecular scaffolds for developing phosphomimetic inhibitors, stabilized peptide therapeutics, and targeted delivery systems
Retatrutide is a triple agonist at GIP, GLP-1, and glucagon receptors
Human absorption may differ
Retatrutide is an unlicensed investigational peptide in the UK with no MHRA or EMA marketing authorisation as of 2024
Allergic Reactions: Although rare, hypersensitivity to cyanocobalamin can occur